Logo Medical Science Monitor

Call: +1.631.470.9640
Closed: National Holiday

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

PARP inhibition is therapeutic in CNS inflammation through immunomodulation

D. Hooper, R. Kean, T. Mikheeva, J. Mabley, C. Szabo, G. Scott

Med Sci Monit 2003; 9(1): 28- :: ID: 15080


We have used a novel phenathridinone PARP inhibitor, PJ-34, to probe the contribution of PARP to the pathogenesis of the multiple sclerosis model, experimental allergic encephalomyelitis (EAE). PJ-34 administration to mice immunized with myelin basic protein (MBP) significantly reduced the incidence of the disease as well as delayed the onset and reduced the severity of clinical signs of EAE in the treated mice that became sick. The loss of blood-brain barrier (BBB) integrity that facilitates immune/inflammatory cell invasion into central nervous system (CNS) tissues in EAE was inhibited by PJ-34, as was T cell infiltration into the CNS. On the other hand, the accumulation of activated monocytes in the CNS was only partly inhibited in PJ-34-treated mice that remained healthy and similar to that of diseased controls in mice where treatment was less effective. Similar patterns were seen for the expression of TNF-a, ICAM-1, IFN-g, and iNOS in CNS tissues in that PJ-34-treated mice with EAE resembled sick controls and treated mice that remained healthy were comparable to normal mice. While PJ-34 did not affect MBP-specific T cell proliferation in vitro, the proliferative response of T cells from PJ-34-treated mice immunized with MBP was reduced. The isotype profile of the antigen-specific antibodies elicited by MBP immunization was also altered, from predominantly IgG2a to IgG1 and IgG2b, by PJ-34 treatment. These results indicate that PARP inhibition is therapeutic in EAE by changing the bias of the response to MBP from pathogenic Th1-associated CNS inflammation to a Th-2 dependent humoral response.

Keywords: CNS, MS/EAE, T cells

Add Comment 0 Comments

228 0


01 May 2023 : Editorial  

Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.940911

Med Sci Monit 2023; 29:e940911

In Press

28 May 2023 : Database Analysis  

Scientometric and Visualized Analysis of Intravoxel Incoherent Motion Magnetic Resonance Imaging: 1988-2021

Med Sci Monit In Press; DOI: 10.12659/MSM.938715  

25 May 2023 : Database Analysis  

The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.940904  

25 May 2023 : Review article  

A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drug...

Med Sci Monit In Press; DOI: 10.12659/MSM.940635  

25 May 2023 : Clinical Research  

Periapical Lesions and Missed Canals in Endodontically Treated Teeth: A Cone-Beam Computed Tomographic Stud...

Med Sci Monit In Press; DOI: 10.12659/MSM.940533  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750